Skip to content
Back to library
Obesity

8 in 10 Tumors Responded: Early Results for a New Targeted Combination in a Common Pancreatic Cancer Mutation

8 in 10 Tumors Responded: Early Results for a New Targeted Combination in a Common Pancreatic Cancer Mutation Response rates in metastatic pancreatic cancer have historically been…

8 in 10 Tumors Responded: Early Results for a New Targeted Combination in a Common Pancreatic Cancer Mutation

Response rates in metastatic pancreatic cancer have historically been measured in the teens, or low twenties at best. So when early-phase data presented in 2026 showed objective response rates above 80% in a specific subgroup of pancreatic cancer patients, it was the kind of result that makes an oncologist pay close attention, while also asking hard questions about how early and how fragile that number really is.

The mutation and the drug

The data concern zoldonrasib, an experimental oral medication that selectively targets tumors carrying a RAS G12D mutation, one of the most common genetic drivers in pancreatic cancer, present in a substantial share of cases. This is a different, more selective cousin of daraxonrasib, the broader RAS(ON) inhibitor already discussed on this site and newly incorporated into ESMO treatment guidelines; zoldonrasib is designed specifically for the G12D mutation subtype rather than the full range of RAS G12 mutations.

Two separate early-phase studies, both from Revolution Medicines, were presented together, testing zoldonrasib in different combinations and different patient populations.

First-line results: zoldonrasib plus standard chemotherapy

In previously untreated patients with metastatic, RAS G12D-mutated pancreatic cancer, zoldonrasib was combined with one of the two standard first-line chemotherapy backbones. In the group receiving zoldonrasib with modified FOLFIRINOX chemotherapy (41 patients), the objective response rate was 82%, with a disease control rate of 96%. In the group receiving zoldonrasib with gemcitabine plus nab-paclitaxel (40 patients), the objective response rate was 61%, with a disease control rate of 90%. For context, response rates with chemotherapy alone in this setting have typically ranged from roughly 25 to 50% depending on the regimen, making these early numbers notably higher, though this was not a randomized, head-to-head comparison against chemotherapy alone.

Previously treated patients: zoldonrasib plus daraxonrasib

In a separate study of 60 patients who had already received one or more prior lines of treatment, zoldonrasib was combined with daraxonrasib itself. Among patients receiving this as second-line treatment, the objective response rate was 50%, with a 6-month progression-free survival rate of 71% and 6-month overall survival of 89%. Among patients receiving it as third-line treatment or later, typically the hardest group to treat, the objective response rate was 47%, with median overall survival reaching 10.5 months, a notable figure for such heavily pretreated patients.

Safety considerations

Side effects were manageable but real. In the chemotherapy combination arms, severe (Grade 3 or higher) treatment-related side effects occurred in 61% of patients on the FOLFIRINOX combination and 80% on the gemcitabine-based combination, mostly blood count changes and fatigue typical of chemotherapy itself. In the daraxonrasib combination arm, severe side effects occurred in 35% of patients, most commonly rash, anemia, and mouth or throat inflammation. Importantly, no treatment-related deaths occurred in either study, and discontinuation rates due to side effects were relatively low in the daraxonrasib combination arm.

Reading these results with appropriate caution

I want to be direct about the limitations here, because early, uncontrolled data in oncology can generate excitement that outruns the evidence. These were small, early-phase (phase 1/2) studies without a randomized comparison group, meaning we cannot be certain how much of this benefit would hold up against a matched control arm, or how durable these responses will prove over longer follow-up. Objective response rate, while meaningful, is not the same as overall survival, the outcome that ultimately matters most to patients. Larger, randomized phase 3 trials will be needed before these combinations can be considered standard practice, and neither of these specific regimens has regulatory approval.

That said, for a cancer where improvements in response rate have historically come in small increments, data suggesting that 8 in 10 tumors are shrinking or stabilizing with a targeted first-line combination represents a genuinely significant signal. For patients whose tumors carry a RAS G12D mutation, identified through the kind of molecular testing increasingly recommended as standard practice, these early results are a meaningful reason for cautious optimism, and a strong argument for considering enrollment in the larger trials that are likely to follow.

Source: Revolution Medicines, presented at the ESMO Gastrointestinal Cancers Congress 2026 (Abstracts 340O and 341O), July 2, 2026.


Share this article

Related articles

Have questions about your own health?

Ask the AI Knowledge Center — trained on Professor Jamal's own publications and guidelines — or book a consultation in person.